Phase 1RecruitingNCT06609356
Adjunct therapy to reduce iatrogenic hyperinsulinemia in T1D
Early-phase adjunct-therapy trial targeting cardiometabolic effects of reducing iatrogenic hyperinsulinemia in type 1 diabetes.
Primary endpoints
- Aim 1: Tissue glucose disposal (TGD)
- Aim 2: Nitric Oxide (NO) bioavailability
Results so far
No results posted yet.